Allergan, Mimetogen partner to develop tavilermide topical dry eye treatment
As per the terms of the licensing deal, Allergan will fund phase 3 development of tavilermide. Mimetogen will receive an upfront payment of $50m from Allergan. The deal
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The objective is to develop an original and non-invasive therapeutic medical device for children with ADHD. Developed in close collaboration with neuroscientists and clinicians, the personalized medical solution